Abivax SA (FR:ABVX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Abivax, a clinical-stage biotech company, has disclosed its share capital and voting rights as of May 31, 2024, revealing a total of 62,930,818 shares and 69,950,376 theoretical voting rights. The company, known for developing treatments for chronic inflammatory diseases, reported 69,938,945 exercisable voting rights, excluding shares without voting rights.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
